INBS Stock Overview
Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Intelligent Bio Solutions Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.47 |
| 52 Week High | US$49.20 |
| 52 Week Low | US$2.28 |
| Beta | 4.83 |
| 1 Month Change | -42.15% |
| 3 Month Change | -6.01% |
| 1 Year Change | -91.32% |
| 3 Year Change | -99.74% |
| 5 Year Change | n/a |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| INBS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -11.8% | 1.6% | 1.0% |
| 1Y | -91.3% | -1.4% | 21.9% |
Return vs Industry: INBS underperformed the US Medical Equipment industry which returned -0.5% over the past year.
Return vs Market: INBS underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| INBS volatility | |
|---|---|
| INBS Average Weekly Movement | 59.7% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INBS's share price has been volatile over the past 3 months.
Volatility Over Time: INBS's weekly volatility has increased from 38% to 60% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 51 | Harry Simeonidis | ibs.inc |
Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.
Intelligent Bio Solutions Inc. Fundamentals Summary
| INBS fundamental statistics | |
|---|---|
| Market cap | US$7.03m |
| Earnings (TTM) | -US$13.40m |
| Revenue (TTM) | US$2.46m |
2.9x
P/S Ratio-0.5x
P/E RatioIs INBS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INBS income statement (TTM) | |
|---|---|
| Revenue | US$2.46m |
| Cost of Revenue | US$1.95m |
| Gross Profit | US$514.20k |
| Other Expenses | US$13.91m |
| Earnings | -US$13.40m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.71 |
| Gross Margin | 20.90% |
| Net Profit Margin | -544.54% |
| Debt/Equity Ratio | 19.1% |
How did INBS perform over the long term?
See historical performance and comparison